|
Медико-биологический
информационный портал
|
 |
для специалистов |
|
|
|
Vol. 21, Art. 17 (pp. 195-203) | 2020
The effect of α2-adrenoreceptor antagonists on cardiovascular system function indicators in the event of an overdose of dexmedetomidine
State Research Testing Institute of Military Medicine
Brief summary
The dynamics of changes of cardiovascular system functioning following overdose of selective α2-adrenoreceptor agonist - dexmedetomidine (DDM), that is used in clinical practice as a component of combined anesthesia as well as for achievement of deep sedation following complicated diagnostic procedures was studied. The significant decrease of heart contraction, values of blood pressure, peripheral circulation as well as increase of troponin in animal blood (white outbred male mice) at 0,15 mg/kg of intravenous dexmedetomidine injection, inducing deep sedation in rats with loss of ability to move independently and react on external stimulus was revealed. Electrocardiography data analysis showed the signs of miocard ischemia. The influence of α2-adrenoreceptor antagonists, having various selectivity and affinity to α2-adrenoreceptors, on values of cardiovascular system functioning and recovery periods of orthostatic position following DMM overdosing is studied. It was revealed that atipamezole and efaroxan showed more effectiveness in comparison with idazoxan and yohimbinum according to withdrawal rate of deep sedation state and recovery of ability for self-contained movement. It was shown that following atipamezole and efaroxan therapy at a dose 0,75 mg/kg a rapid recovery of cardiovascular system takes place. Moreover, the application of this α2-adrenoreceptor antagonist allows one to prevent the development of ischemic changes in myocardium. Thus, the research results allow us to consider atipamezole and efaroxan as perspective drugs for the development of dosage forms for emergency medical aid following dexmedetomidine overdosage in clinical practice. Key words dexmedetomidine overdosage, atipamezole, anesthesia, cardiovascular system, α2 - adrenoreceptor antagonists (The article in PDF format. For preview need Adobe Acrobat Reader)  Open article in new window
Reference list 1. Kozlov I.A., Klipa T.V., Antonov I.O. Deksmedetomidin kak kardioprotektor v kardiohiryrgii (obzor) / Obshaya reanimatologiya. 2017; N 13 (4). S. 44-63. 2. Kamibayashi T., Maze M. Clinical Uses of α2-Adrenergic Agonists / Anesthesiology. 2000. Vol. 93 (5). R. 1345-1349. https://doi.org/10.1097/00000542-200011000-00030. 3. Maze M., Virtanen R., Daunt D. Effects of dexmedetomidine a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg 1991; 73 (2): 204-208. https://doi.org/10.1213/00000539-199108000-00015. 4. Siddappa B., Biggins J., Karriyanna S., Calkins P., Rotta A.T. High-dose dexmedetomidine sedation for pediatric MRI. / Paediatr.Anaesth. 2011. Vol. 21(2). R. 153-8. https://doi.org/10.1111/j.1460-9592.2010.03502.x. 5. Ebert T.J., Hall E.J., Barney J.A. The Effects of Increasing Plasma Concentrations of Dexmedetomidine in Humans. / Anesthesiology 2000. Vol. 93 (2). R. 382-394. https://doi.org/10.1097/00000542-200008000-00016. 6. Gilsbach R., Hein L. Are the pharmacology and physiology of α2-adrenoreceptors determined by α2-heteroreceptors and autoreceptors respectively? / Br.J. Pharmacol. 2012 Vol. 165 (1). R. 90-102. https://doi.org/10.1111/j.1476-5381.2011.01533.x. |
|||||||||
Articles
| Размещение рекламы | |
| |
 |